ILMN
Illumina, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Capital expenditures for free cash flow purposes | $148M | Fiscal Year 2025 | — |
| Free cash flow non-GAAP | $931M | Fiscal Year 2025 | — |
| Non-GAAP operating margin non-GAAP | 23.1% | Fiscal Year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ILMN
this stock
Illumina, Inc.
|
$29.32B | +43.2% | -0.7% | 34.2 | 6.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$194.99B | -11.9% | +0.4% | 28.9 | 1.2% |
|
DHR
Danaher Corp /De/
|
$135.02B | -16.3% | +8.5% | 36.8 | 1.6% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.06B | -17.9% | +10.4% | 41.1 | 2.7% |
|
NTRA
Natera, Inc.
|
$40.33B | +19.8% | -2.8% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ILMN | +6.8% | +18.8% | +27.8% | +6.8% | +43.2% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +7.0% | +18.0% | +20.3% | +7.0% | +33.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.